Stoll Joins Soliton as Senior Director of Clinical Development

Rapid Acoustic Pulse Device

Mary Stoll is the new senior director of clinical development Soliton, a medical device manufacturer with a novel and proprietary acoustic pulse platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Stoll will be responsible for direct oversight of all clinical activities of the company’s Rapid Acoustic Pulse (RAP) device for tattoo removal, improvement in the appearance of cellulite and keloid scarring, and additional pipeline indications.

Chicago Cosmetic Surgery and Dermatology Joins Soliton Pivotal Cellulite Trial

Soliton, a medical device company with a novel and proprietary rapid pulse acoustic shockwave technology licensed from The University of Texas, has brought on supervising physicians Omer Ibrahim, MD, FAAD, and Carolyn I. Jacob, MD, FAAD, as well as a third study site for its upcoming expanded pivotal Cellulite Clinical Trial. The site, Chicago Cosmetic Surgery and Dermatology, joins two previously identified sites in what is anticipated to be a four-site trial.